Cannabinoids: Medical implications

Herbal cannabis has been used for thousands of years for medical purposes. With elucidation of the chemical structures of tetrahydrocannabinol (THC) and cannabidiol (CBD) and with discovery of the human endocannabinoid system, the medical usefulness of cannabinoids has been more intensively explored...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of medicine (Helsinki) 2016-04, Vol.48 (3), p.128-141
Hauptverfasser: Schrot, Richard J., Hubbard, John R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 141
container_issue 3
container_start_page 128
container_title Annals of medicine (Helsinki)
container_volume 48
creator Schrot, Richard J.
Hubbard, John R.
description Herbal cannabis has been used for thousands of years for medical purposes. With elucidation of the chemical structures of tetrahydrocannabinol (THC) and cannabidiol (CBD) and with discovery of the human endocannabinoid system, the medical usefulness of cannabinoids has been more intensively explored. While more randomized clinical trials are needed for some medical conditions, other medical disorders, like chronic cancer and neuropathic pain and certain symptoms of multiple sclerosis, have substantial evidence supporting cannabinoid efficacy. While herbal cannabis has not met rigorous FDA standards for medical approval, specific well-characterized cannabinoids have met those standards. Where medical cannabis is legal, patients typically see a physician who "certifies" that a benefit may result. Physicians must consider important patient selection criteria such as failure of standard medical treatment for a debilitating medical disorder. Medical cannabis patients must be informed about potential adverse effects, such as acute impairment of memory, coordination and judgment, and possible chronic effects, such as cannabis use disorder, cognitive impairment, and chronic bronchitis. In addition, social dysfunction may result at work/school, and there is increased possibility of motor vehicle accidents. Novel ways to manipulate the endocannbinoid system are being explored to maximize benefits of cannabinoid therapy and lessen possible harmful effects. Key messages The medical disorders with the current best evidence that supports a benefit for cannabinoid use are the following: multiple sclerosis patient-reported symptoms of spasticity (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis central pain or painful spasms (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis bladder frequency (nabiximols), and chronic cancer pain/neuropathic pain (nabiximols and smoked THC). Herbal cannabis has not met rigorous US FDA standards for medical approval, while specific well-characterized cannabinoids have met those standards, and more are being studied. However, herbal cannabis is legal for medical use in certain US states/countries, and patients must usually see a physician who "certifies" that a benefit may result. Participating physicians should be knowledgeable about cannabinoids, closely look at the risk/benefit ratio, and consider certain important criteria in selecting a patient, such as: age, severity, and
doi_str_mv 10.3109/07853890.2016.1145794
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_07853890_2016_1145794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1777978568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-38bb6483983657d54dc3b6eaf799b52deb14d87c509e4176e0b3dc4fa33f99d3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_glI8edmabL42npTiF1S89B7yCZHdTU22SP-9Wdp69DRzeGbemQeAawQXGEFxD3lDcSPgooaILRAilAtyAqYIM1rVkMFTMB2ZaoQm4CLnLwhhzRE8B5OaCVTjhk7B7VL1vdKhj8Hmh_mHs8Godh66TVuaIcQ-X4Izr9rsrg51BtYvz-vlW7X6fH1fPq0qgxkbSo7WjDRYNOUCbimxBmvmlOdCaFpbpxGxDTcUCkcQZw5qbA3xCmMvhMUzcLdfu0nxe-vyILuQjWtb1bu4zRJxzkV5iDUFpXvUpJhzcl5uUuhU2kkE5WhHHu3I0Y482ClzN4eIre6c_Zs66ijA4x4IvY-pUz8xtVYOatfG5JPqTcjj_v8yfgHVn3JW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777978568</pqid></control><display><type>article</type><title>Cannabinoids: Medical implications</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Schrot, Richard J. ; Hubbard, John R.</creator><creatorcontrib>Schrot, Richard J. ; Hubbard, John R.</creatorcontrib><description>Herbal cannabis has been used for thousands of years for medical purposes. With elucidation of the chemical structures of tetrahydrocannabinol (THC) and cannabidiol (CBD) and with discovery of the human endocannabinoid system, the medical usefulness of cannabinoids has been more intensively explored. While more randomized clinical trials are needed for some medical conditions, other medical disorders, like chronic cancer and neuropathic pain and certain symptoms of multiple sclerosis, have substantial evidence supporting cannabinoid efficacy. While herbal cannabis has not met rigorous FDA standards for medical approval, specific well-characterized cannabinoids have met those standards. Where medical cannabis is legal, patients typically see a physician who "certifies" that a benefit may result. Physicians must consider important patient selection criteria such as failure of standard medical treatment for a debilitating medical disorder. Medical cannabis patients must be informed about potential adverse effects, such as acute impairment of memory, coordination and judgment, and possible chronic effects, such as cannabis use disorder, cognitive impairment, and chronic bronchitis. In addition, social dysfunction may result at work/school, and there is increased possibility of motor vehicle accidents. Novel ways to manipulate the endocannbinoid system are being explored to maximize benefits of cannabinoid therapy and lessen possible harmful effects. Key messages The medical disorders with the current best evidence that supports a benefit for cannabinoid use are the following: multiple sclerosis patient-reported symptoms of spasticity (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis central pain or painful spasms (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis bladder frequency (nabiximols), and chronic cancer pain/neuropathic pain (nabiximols and smoked THC). Herbal cannabis has not met rigorous US FDA standards for medical approval, while specific well-characterized cannabinoids have met those standards, and more are being studied. However, herbal cannabis is legal for medical use in certain US states/countries, and patients must usually see a physician who "certifies" that a benefit may result. Participating physicians should be knowledgeable about cannabinoids, closely look at the risk/benefit ratio, and consider certain important criteria in selecting a patient, such as: age, severity, and nature of the medical disorder, prior or current serious psychiatric or substance use disorder, failure of standard medical therapy as well as failure of an approved cannabinoid, serious underlying cardiac/pulmonary disease, agreement to follow-up visits, and acceptance of the detailed explanation of potential adverse risks. The limitations of use of medical cannabis include the following potential adverse effects that are discussed with potential patients: acute central nervous system effects such as deficits in memory, judgment, attention, coordination, and perception (such as time and color), anxiety, dysphoria, and psychosis; chronic central nervous system effects such as cannabis use disorder, cognitive and memory deficits, and increased risk of psychosis; pulmonary effects such as chronic bronchitis; social dysfunction, such as work/school; increased risk of accidents, such as motor vehicle accidents; and preliminary data suggest possible risk for acute cardiovascular event, especially with underlying heart disease. The normal human endocannabinoid system is important in the understanding of such issues as normal physiology, cannabis use disorder, and the development of medications that may act as agonists or antagonists to CB1 and CB2. By understanding the endocannabinoid system, it may be possible to enhance the beneficial effects of cannabinoid-related medication, while reducing the harmful effects.</description><identifier>ISSN: 0785-3890</identifier><identifier>EISSN: 1365-2060</identifier><identifier>DOI: 10.3109/07853890.2016.1145794</identifier><identifier>PMID: 26912385</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Analgesics, Non-Narcotic - therapeutic use ; cannabinoid treatment ; Cannabinoids ; Cannabinoids - adverse effects ; Cannabinoids - standards ; Cannabinoids - therapeutic use ; Cannabis - chemistry ; Drug and Narcotic Control ; Endocannabinoids - metabolism ; Humans ; Marijuana Abuse - prevention &amp; control ; medical marijuana ; Medical Marijuana - adverse effects ; Medical Marijuana - standards ; Medical Marijuana - therapeutic use ; Meta-Analysis as Topic ; Pain - drug therapy ; Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; Receptors, Cannabinoid - metabolism ; United States</subject><ispartof>Annals of medicine (Helsinki), 2016-04, Vol.48 (3), p.128-141</ispartof><rights>2016 Informa UK Limited, trading as Taylor &amp; Francis Group 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-38bb6483983657d54dc3b6eaf799b52deb14d87c509e4176e0b3dc4fa33f99d3</citedby><cites>FETCH-LOGICAL-c366t-38bb6483983657d54dc3b6eaf799b52deb14d87c509e4176e0b3dc4fa33f99d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26912385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schrot, Richard J.</creatorcontrib><creatorcontrib>Hubbard, John R.</creatorcontrib><title>Cannabinoids: Medical implications</title><title>Annals of medicine (Helsinki)</title><addtitle>Ann Med</addtitle><description>Herbal cannabis has been used for thousands of years for medical purposes. With elucidation of the chemical structures of tetrahydrocannabinol (THC) and cannabidiol (CBD) and with discovery of the human endocannabinoid system, the medical usefulness of cannabinoids has been more intensively explored. While more randomized clinical trials are needed for some medical conditions, other medical disorders, like chronic cancer and neuropathic pain and certain symptoms of multiple sclerosis, have substantial evidence supporting cannabinoid efficacy. While herbal cannabis has not met rigorous FDA standards for medical approval, specific well-characterized cannabinoids have met those standards. Where medical cannabis is legal, patients typically see a physician who "certifies" that a benefit may result. Physicians must consider important patient selection criteria such as failure of standard medical treatment for a debilitating medical disorder. Medical cannabis patients must be informed about potential adverse effects, such as acute impairment of memory, coordination and judgment, and possible chronic effects, such as cannabis use disorder, cognitive impairment, and chronic bronchitis. In addition, social dysfunction may result at work/school, and there is increased possibility of motor vehicle accidents. Novel ways to manipulate the endocannbinoid system are being explored to maximize benefits of cannabinoid therapy and lessen possible harmful effects. Key messages The medical disorders with the current best evidence that supports a benefit for cannabinoid use are the following: multiple sclerosis patient-reported symptoms of spasticity (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis central pain or painful spasms (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis bladder frequency (nabiximols), and chronic cancer pain/neuropathic pain (nabiximols and smoked THC). Herbal cannabis has not met rigorous US FDA standards for medical approval, while specific well-characterized cannabinoids have met those standards, and more are being studied. However, herbal cannabis is legal for medical use in certain US states/countries, and patients must usually see a physician who "certifies" that a benefit may result. Participating physicians should be knowledgeable about cannabinoids, closely look at the risk/benefit ratio, and consider certain important criteria in selecting a patient, such as: age, severity, and nature of the medical disorder, prior or current serious psychiatric or substance use disorder, failure of standard medical therapy as well as failure of an approved cannabinoid, serious underlying cardiac/pulmonary disease, agreement to follow-up visits, and acceptance of the detailed explanation of potential adverse risks. The limitations of use of medical cannabis include the following potential adverse effects that are discussed with potential patients: acute central nervous system effects such as deficits in memory, judgment, attention, coordination, and perception (such as time and color), anxiety, dysphoria, and psychosis; chronic central nervous system effects such as cannabis use disorder, cognitive and memory deficits, and increased risk of psychosis; pulmonary effects such as chronic bronchitis; social dysfunction, such as work/school; increased risk of accidents, such as motor vehicle accidents; and preliminary data suggest possible risk for acute cardiovascular event, especially with underlying heart disease. The normal human endocannabinoid system is important in the understanding of such issues as normal physiology, cannabis use disorder, and the development of medications that may act as agonists or antagonists to CB1 and CB2. By understanding the endocannabinoid system, it may be possible to enhance the beneficial effects of cannabinoid-related medication, while reducing the harmful effects.</description><subject>Analgesics, Non-Narcotic - therapeutic use</subject><subject>cannabinoid treatment</subject><subject>Cannabinoids</subject><subject>Cannabinoids - adverse effects</subject><subject>Cannabinoids - standards</subject><subject>Cannabinoids - therapeutic use</subject><subject>Cannabis - chemistry</subject><subject>Drug and Narcotic Control</subject><subject>Endocannabinoids - metabolism</subject><subject>Humans</subject><subject>Marijuana Abuse - prevention &amp; control</subject><subject>medical marijuana</subject><subject>Medical Marijuana - adverse effects</subject><subject>Medical Marijuana - standards</subject><subject>Medical Marijuana - therapeutic use</subject><subject>Meta-Analysis as Topic</subject><subject>Pain - drug therapy</subject><subject>Practice Guidelines as Topic</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptors, Cannabinoid - metabolism</subject><subject>United States</subject><issn>0785-3890</issn><issn>1365-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlZ_glI8edmabL42npTiF1S89B7yCZHdTU22SP-9Wdp69DRzeGbemQeAawQXGEFxD3lDcSPgooaILRAilAtyAqYIM1rVkMFTMB2ZaoQm4CLnLwhhzRE8B5OaCVTjhk7B7VL1vdKhj8Hmh_mHs8Godh66TVuaIcQ-X4Izr9rsrg51BtYvz-vlW7X6fH1fPq0qgxkbSo7WjDRYNOUCbimxBmvmlOdCaFpbpxGxDTcUCkcQZw5qbA3xCmMvhMUzcLdfu0nxe-vyILuQjWtb1bu4zRJxzkV5iDUFpXvUpJhzcl5uUuhU2kkE5WhHHu3I0Y482ClzN4eIre6c_Zs66ijA4x4IvY-pUz8xtVYOatfG5JPqTcjj_v8yfgHVn3JW</recordid><startdate>20160402</startdate><enddate>20160402</enddate><creator>Schrot, Richard J.</creator><creator>Hubbard, John R.</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160402</creationdate><title>Cannabinoids: Medical implications</title><author>Schrot, Richard J. ; Hubbard, John R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-38bb6483983657d54dc3b6eaf799b52deb14d87c509e4176e0b3dc4fa33f99d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analgesics, Non-Narcotic - therapeutic use</topic><topic>cannabinoid treatment</topic><topic>Cannabinoids</topic><topic>Cannabinoids - adverse effects</topic><topic>Cannabinoids - standards</topic><topic>Cannabinoids - therapeutic use</topic><topic>Cannabis - chemistry</topic><topic>Drug and Narcotic Control</topic><topic>Endocannabinoids - metabolism</topic><topic>Humans</topic><topic>Marijuana Abuse - prevention &amp; control</topic><topic>medical marijuana</topic><topic>Medical Marijuana - adverse effects</topic><topic>Medical Marijuana - standards</topic><topic>Medical Marijuana - therapeutic use</topic><topic>Meta-Analysis as Topic</topic><topic>Pain - drug therapy</topic><topic>Practice Guidelines as Topic</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptors, Cannabinoid - metabolism</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schrot, Richard J.</creatorcontrib><creatorcontrib>Hubbard, John R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of medicine (Helsinki)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schrot, Richard J.</au><au>Hubbard, John R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cannabinoids: Medical implications</atitle><jtitle>Annals of medicine (Helsinki)</jtitle><addtitle>Ann Med</addtitle><date>2016-04-02</date><risdate>2016</risdate><volume>48</volume><issue>3</issue><spage>128</spage><epage>141</epage><pages>128-141</pages><issn>0785-3890</issn><eissn>1365-2060</eissn><abstract>Herbal cannabis has been used for thousands of years for medical purposes. With elucidation of the chemical structures of tetrahydrocannabinol (THC) and cannabidiol (CBD) and with discovery of the human endocannabinoid system, the medical usefulness of cannabinoids has been more intensively explored. While more randomized clinical trials are needed for some medical conditions, other medical disorders, like chronic cancer and neuropathic pain and certain symptoms of multiple sclerosis, have substantial evidence supporting cannabinoid efficacy. While herbal cannabis has not met rigorous FDA standards for medical approval, specific well-characterized cannabinoids have met those standards. Where medical cannabis is legal, patients typically see a physician who "certifies" that a benefit may result. Physicians must consider important patient selection criteria such as failure of standard medical treatment for a debilitating medical disorder. Medical cannabis patients must be informed about potential adverse effects, such as acute impairment of memory, coordination and judgment, and possible chronic effects, such as cannabis use disorder, cognitive impairment, and chronic bronchitis. In addition, social dysfunction may result at work/school, and there is increased possibility of motor vehicle accidents. Novel ways to manipulate the endocannbinoid system are being explored to maximize benefits of cannabinoid therapy and lessen possible harmful effects. Key messages The medical disorders with the current best evidence that supports a benefit for cannabinoid use are the following: multiple sclerosis patient-reported symptoms of spasticity (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis central pain or painful spasms (nabiximols, nabilone, dronabinol, and oral cannabis extract), multiple sclerosis bladder frequency (nabiximols), and chronic cancer pain/neuropathic pain (nabiximols and smoked THC). Herbal cannabis has not met rigorous US FDA standards for medical approval, while specific well-characterized cannabinoids have met those standards, and more are being studied. However, herbal cannabis is legal for medical use in certain US states/countries, and patients must usually see a physician who "certifies" that a benefit may result. Participating physicians should be knowledgeable about cannabinoids, closely look at the risk/benefit ratio, and consider certain important criteria in selecting a patient, such as: age, severity, and nature of the medical disorder, prior or current serious psychiatric or substance use disorder, failure of standard medical therapy as well as failure of an approved cannabinoid, serious underlying cardiac/pulmonary disease, agreement to follow-up visits, and acceptance of the detailed explanation of potential adverse risks. The limitations of use of medical cannabis include the following potential adverse effects that are discussed with potential patients: acute central nervous system effects such as deficits in memory, judgment, attention, coordination, and perception (such as time and color), anxiety, dysphoria, and psychosis; chronic central nervous system effects such as cannabis use disorder, cognitive and memory deficits, and increased risk of psychosis; pulmonary effects such as chronic bronchitis; social dysfunction, such as work/school; increased risk of accidents, such as motor vehicle accidents; and preliminary data suggest possible risk for acute cardiovascular event, especially with underlying heart disease. The normal human endocannabinoid system is important in the understanding of such issues as normal physiology, cannabis use disorder, and the development of medications that may act as agonists or antagonists to CB1 and CB2. By understanding the endocannabinoid system, it may be possible to enhance the beneficial effects of cannabinoid-related medication, while reducing the harmful effects.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>26912385</pmid><doi>10.3109/07853890.2016.1145794</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0785-3890
ispartof Annals of medicine (Helsinki), 2016-04, Vol.48 (3), p.128-141
issn 0785-3890
1365-2060
language eng
recordid cdi_crossref_primary_10_3109_07853890_2016_1145794
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Analgesics, Non-Narcotic - therapeutic use
cannabinoid treatment
Cannabinoids
Cannabinoids - adverse effects
Cannabinoids - standards
Cannabinoids - therapeutic use
Cannabis - chemistry
Drug and Narcotic Control
Endocannabinoids - metabolism
Humans
Marijuana Abuse - prevention & control
medical marijuana
Medical Marijuana - adverse effects
Medical Marijuana - standards
Medical Marijuana - therapeutic use
Meta-Analysis as Topic
Pain - drug therapy
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Receptors, Cannabinoid - metabolism
United States
title Cannabinoids: Medical implications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A02%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cannabinoids:%20Medical%20implications&rft.jtitle=Annals%20of%20medicine%20(Helsinki)&rft.au=Schrot,%20Richard%20J.&rft.date=2016-04-02&rft.volume=48&rft.issue=3&rft.spage=128&rft.epage=141&rft.pages=128-141&rft.issn=0785-3890&rft.eissn=1365-2060&rft_id=info:doi/10.3109/07853890.2016.1145794&rft_dat=%3Cproquest_cross%3E1777978568%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777978568&rft_id=info:pmid/26912385&rfr_iscdi=true